<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062942</url>
  </required_header>
  <id_info>
    <org_study_id>OFI INJ - 1.0</org_study_id>
    <nct_id>NCT04062942</nct_id>
  </id_info>
  <brief_title>The Six-Minute Walking Test (6WT) and Timed-Up-and-Go (TUG) Test as Measures of Objective Functional Impairment in Patients Undergoing Interlaminar or Transforaminal Epidural Steroid Injection for Lumbar Degenerative Disc Disease (DDD)</brief_title>
  <official_title>The Six-Minute Walking Test (6WT) and Timed-Up-and-Go (TUG) Test as Measures of Objective Functional Impairment in Patients Undergoing Interlaminar or Transforaminal Epidural Steroid Injection for Lumbar Degenerative Disc Disease (DDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Dr. Astrid Weyerbrock, Klinik für Neurochirurgie, Kantonsspital St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PD Dr. med. Martin Stienen, Klinik für Neurochirurgie, Universitätsspital Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PD Dr. med. David Bellut, Klinik für Neurochirurgie, Universitätsspital Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>med. pract. Markéta Sosnová, Klinik für Neurochirurgie, Kantonsspital St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>med. pract. Michal Ziga, Klinik für Neurochirurgie, Kantonsspital St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>med. pract.Valentin Steinsiepe, Klinik für Neurochirurgie, Kantonsspital St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. med. Anna Zeitlberger, Klinik für Neurochirurgie, Kantonsspital St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PD Dr. med. Oliver Gautschi, Neuro- und Wirbelsäulen Zentrum Zentralschweiz, Luzern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cantonal Hospital of St. Gallen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the validity of the Six-Minute-Walking Test (6WT) and
      Timed-Up and Go (TUG) test to measure objective functional impairment (OFI) in patients
      undergoing either interlaminar epidural steroid injection (ESI) or transforaminal epidural
      steroid injections (TFESI) for lumbar degenerative disc disease (DDD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of the project are to assess the ability of the Six-Minute-Walking Test (6WT)
      and Timed-Up and Go (TUG) test to measure and classify the disease burden, and to determine
      their relation to already established subjective patient reported outcome measures (PROMs)in
      patients treated with either interlaminar epidural steroid injection (ESI) or transforaminal
      epidural steroid injections (TFESI) for lumbar degenerative disc disease (DDD). No research
      has so far determined its validity to determine OFI in a cohort of patients managed
      conservatively. We want to use an existing smartphone-applications for the 6WT and TUG test.
      Applying self-measurement of the 6WT within the context of a two center observational study
      will determine OFI in patients before and after (TF)ESI. The results of this study add to the
      understanding of achievable objective outcomes after steroid injection applied to patients
      with DDD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Raw Walking distance</measure>
    <time_frame>2-6 weeks</time_frame>
    <description>The difference in 6WD (in m), as measured with the 6WT, between the baseline (before injection) and 4-week (range 2-6 weeks) follow-up assessment (after injection).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Raw Walking distance - day 1</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in Six-minute-walking test (6WD, in m) between baseline and 1-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raw Walking distance - day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Difference in 6WD (in m) between baseline and 7-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTFS and DTFS - day 1</measure>
    <time_frame>1 day</time_frame>
    <description>Difference in Time to first symptoms (TTFS, in sec) and Distance to First Symptoms (DTFS, in m), as measured by the 6WT, between the baseline and 1-day follow-up assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTFS and DTFS - day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Difference in TTFS and DTFS, as measured by the 6WT, between the baseline and 7-days follow-up assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTFS and DTFS - 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Difference in TTFS and DTFS, as measured by the 6WT, between the baseline and 4 weeks follow-up assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODI</measure>
    <time_frame>4 weeks</time_frame>
    <description>Difference in PROM, as measured by the Oswestry Disability Index (ODI score, range 0% (best) - 100% (worst)), between the baseline- and 4-week follow-up assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COMI</measure>
    <time_frame>4 weeks</time_frame>
    <description>Difference in PROM, as measured by the Core Outcome Measure Index (COMI score, range 0 (best) - 10 (worst)), between the baseline- and 4-week follow-up assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF -12</measure>
    <time_frame>4 weeks</time_frame>
    <description>Difference in in health-related quality of life (hrQoL), as measured by the SF-12 score (SF-12 score, range 0 (worst) - 1 (best)), between the baseline- and 4-week follow-up assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Difference in pain intensity, as measured by the NRS pain scale (NRS pain score, range 0 (best) - 10 (worst)), between the baseline- and 1-day, 7-day and 4-week follow-up assess-ments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation 6WD/ODI</measure>
    <time_frame>4 weeks</time_frame>
    <description>Correlation of 6WD with the ODI score at baseline and 4-week follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation 6WD/COMI</measure>
    <time_frame>4 weeks</time_frame>
    <description>Correlation of 6WD with the COMI score at baseline and 4-week follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation 6WD/SF-12</measure>
    <time_frame>4 weeks</time_frame>
    <description>Correlation of 6WD with the SF-12 score at baseline and 4-week follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation 6WD/NRS Pain</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Correlation of 6WD with the NRS pain score at baseline and 1-day, 7-days and 4-week follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation 6WD/TUG</measure>
    <time_frame>4 weeks</time_frame>
    <description>Correlation of 6WD with the TUG test at baseline and 4-week follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TUG T-Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Difference in TUG T-score between the baseline (before injection) and 4-week follow-up assessment (after injection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations TUG/PROMS</measure>
    <time_frame>4 weeks</time_frame>
    <description>Correlation of TUG T-score with the ODI/COMI/NRS Pain/SF-12 score at baseline and follow up</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lumbar Disc Disease</condition>
  <condition>Lumbar Spine Degeneration</condition>
  <condition>Lumbar Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>DDD patients</arm_group_label>
    <description>All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen
        (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria
        and scheduled for ESI or TFESI will be considered for this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with symptomatic lumbar Degenerate Disc Disease (DDD), scheduled for either
             either interlaminar epidural steroid injection (ESI) or transforaminal epidural
             steroid injections (TFESI)

          -  Male and Female subjects ≥ 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Inability to walk (extreme pain or severe neurological deficits)

          -  Severe Chronic Obstructive Lung Disease (COPD) corresponding to ≥ Gold III

          -  Severe heart failure corresponding to ≥ New York Heart Association (NYHA) III

          -  Lung cancer and diffuse parenchymal lung disease

          -  Other medical reasons interfering with the patient's ability to walk and perform the
             6WT/TUG (e.g., osteoarthritis disease of the lower extremities, Parkinson's disease,
             heart failure, hip or knee prosthesis etc.)

          -  Unavailability for follow up and/or inability to complete assessment (planning to
             move, no smartphone, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nicolai Maldaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital St. Gallen / Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Stienen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsspital Zürich / Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolai Maldaner, MD</last_name>
    <phone>+41 71 494 11 99</phone>
    <email>nicolai.maldaner@kssg.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen / Department of Neurosurgery</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolai Maldaner, MD</last_name>
      <phone>+41 71 494 11 99</phone>
      <email>nicolai.maldaner@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich / Department of Neurosurgery</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Stienen, MD</last_name>
      <phone>+41 44 255 15 20</phone>
      <email>martin.stienen@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Stienen MN, Ho AL, Staartjes VE, Maldaner N, Veeravagu A, Desai A, Gautschi OP, Bellut D, Regli L, Ratliff JK, Park J. Objective measures of functional impairment for degenerative diseases of the lumbar spine: a systematic review of the literature. Spine J. 2019 Jul;19(7):1276-1293. doi: 10.1016/j.spinee.2019.02.014. Epub 2019 Mar 2.</citation>
    <PMID>30831316</PMID>
  </reference>
  <results_reference>
    <citation>Stienen MN, Maldaner N, Joswig H, Corniola MV, Bellut D, Prömmel P, Regli L, Weyerbrock A, Schaller K, Gautschi OP. Objective functional assessment using the &quot;Timed Up and Go&quot; test in patients with lumbar spinal stenosis. Neurosurg Focus. 2019 May 1;46(5):E4. doi: 10.3171/2019.2.FOCUS18618.</citation>
    <PMID>31042663</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital of St. Gallen</investigator_affiliation>
    <investigator_full_name>Nicolai Maldaner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Spinal Diseases</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

